Cryoport Reports Strong FY25 Net Income Driven by Divestiture Gain and Improved Continuing Operations

summarizeSummary

Cryoport reported a net income of $78.3 million for fiscal year 2025, a major turnaround from a prior-year loss, driven by a significant gain from the CRYOPDP divestiture and improved core operations, alongside a strengthened cash position and ongoing share repurchase authorization.

check_boxKey Events

• Full Year 2025 Net Income

  Cryoport reported a net income of $78.3 million for the year ended December 31, 2025, a significant improvement from a net loss of $114.8 million in 2024.

• CRYOPDP Business Divestiture

  The company completed the divestiture of its CRYOPDP business on June 11, 2025, for $133.0 million, plus repayment of $77.2 million in intercompany loans, resulting in a $116.953 million gain on disposal.

• Improved Continuing Operations

  Loss from continuing operations narrowed to $34.0 million in 2025, a substantial reduction from $104.7 million in 2024, indicating improved core business performance.

• Strong Cash Position

  Cash and cash equivalents significantly increased to $250.5 million at year-end 2025, up from $34.1 million in 2024, bolstered by divestiture proceeds.

auto_awesomeAnalysis

Cryoport's Annual Report on Form 10-K reveals a significant financial turnaround in fiscal year 2025, primarily driven by the successful divestiture of its CRYOPDP business. The company reported a net income of $78.3 million, a substantial improvement from a net loss of $114.8 million in the prior year. This positive shift was largely due to a $116.953 million gain on the disposal of the CRYOPDP business. Furthermore, the loss from continuing operations significantly narrowed to $34.0 million from $104.7 million, indicating an improvement in core business performance. The company also ended the year with a robust cash and short-term investments balance of $411.2 million, up from $250.6 million in 2024, providing strong liquidity. Strategic initiatives in the high-growth cell and gene therapy (CGT) market, including new facility openings and product launches, position Cryoport for future growth. Investors should note the continued, albeit reduced, loss from continuing operations and the expiration of $19.7 million in federal NOL carryforwards due to ownership changes.